INS and metabolic dysfunction-associated steatohepatitis: It reduced hepatocyte apoptosis, inflammation, fibrosis (but not steatosis), insulin/leptin resistance, hepatic and circulating triglyceride levels, and the progression to non-alcoholic steatohepatitis (NASH).